Ernexa Therapeutics (ERNA) announced that new data will be presented at the American Society of Clinical Oncology Annual Meeting 2025 on June 2 in Chicago. The study explored the technology behind Ernexa’s novel iMSC-based immunotherapy platform, which uses induced mesenchymal stem cells engineered to secrete cytokines IL-7 and IL-15 directly into ovarian tumors. These iMSCs, derived from adult skin cells, safely migrated into the tumor microenvironment and triggered strong immune activation, including T cell and macrophage infiltration, turning immunologically “cold” tumors into “hot” ones.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERNA: